La vendita allo scoperto per UroGen Pharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di UroGen Pharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

UroGen Pharma (NASDAQ:URGN) Azioni, Report sulle vendite allo scoperto

UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

cancer

Biotech

News

Health Care

Movers

General

URGN

La FDA approva una terapia innovativa per un tumore ricorrente. Un gel che potrebbe mandare in pensione il bisturi per i pazienti.

Cancro alla vescica: arriva il primo farmaco che può sostituire la chirurgia

Iron ore prices have rebounded above $100 for the first time since February. Renewed optimism about China's economic resilience and the announcement of construction of the world's largest hydropower dam drove momentum of the futures market in Singapore.
Yet, some analysts believe the rally is unsustainable given the market dynamics and healthy <a target="_blank" href="https://www.benzinga.com/topic/iron-ore" rel="noreferrer noopener">capacity increases from key producers</a>.
In a note cited <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-07-16/iron-ore-tops-100-for-first-time-since-may-on-china-sentiment" rel="noreferrer noopener">by</a> Bloomberg, Citi strategists, including Shreyas Madabushi, warned that "prices are currently above market fundamentals," suggesting a more modest and gradual decline in steel output rather than an aggressive contraction.
Meanwhile, Rio Tinto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) has fast-tracked its timeline for shipments from the massive Simandou iron ore mine in Guinea. The firm expects to ship 0.5 to 1 million tons this November.
While the monumental project could deliver as much as 120 million tons annually, the ramp-up should remain gradual.
RBC analysts forecast output will reach just 12 million tons in 2026 and not top 48 million until 2028.
RIO's rival BHP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) reported a 14% quarter-on-quarter jump in Q4 iron ore production to 70.3 million tons, helping push annual output to a record 290 million tons.
While oversupply looms, official Chinese economic data indicate strong demand, further supported by Premier Li Quiang's Monday announcement.
Quiang broke news on construction of the world's largest hydropower dam on the Yarlung Tsangpo River. The dam, which is expected to exceed the Three Gorges Dam by at least a factor of three, is expected to drive significant demand for construction-grade steel.
Per China Briefing's <a target="_blank" href="https://www.china-briefing.com/news/chinas-economy-in-h1-2025-gdp-trade-and-fdi-highlights/" rel="noreferrer noopener">report</a>, GDP rose 5.3% year-on-year in the first half of 2025, with industrial output up 6.4%, services growing 5.5%, and retail sales up 5.0%. Fixed asset investment rose 2.8%, led by manufacturing, and disposable income grew 5.4% in real terms. National Bureau of Statistics Deputy Head Sheng Laiyun called the results a "hard-won achievement" amid global volatility.
Former Australian Ambassador to China Geoff Raby noted that Prime Minister Anthony Albanese's latest visit to China provides an opportunity.
"Although China's growth in demand for Australian iron ore is tapering off, the absolute volume we sell is so large that even a small uptick in demand will lead to tremendous increases in volume," Raby <a target="_blank" href="https://www.youtube.com/watch?v=VuBsZheeGB8" rel="noreferrer noopener">told</a> ABC. "It's a two-way relationship," he added, arguing that China's pivot to green steel is not a threat, but a future opportunity for Australian producers.
"We have massive potential in terms of renewable energy. Ross Garnaut has written about this on numerous occasions in books, and he talks about Australia being the energy superpower of the future because of this very reason."
Raby also clarified that Australia must balance its engagement with China against global pressures, especially from the U.S.
"The Prime Minister has stuck to our strong commitment to free trade, and has not gone down the path of retaliatory tariffs. So, I think that puts us in a very strong position," he said.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/node/46438534" target="_blank" rel="noreferrer noopener">Three Factors Keeping Gold's Momentum In 2025: Report</a></li>
</ul>
Photo by saweang.w via Shutterstock

Asia

Commodities

Politics

Global

Markets

China-Led Rally Sends Iron Ore Over $100 Despite Looming Oversupply

TD Cowen analyst Bill Katz upgrades Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) from Hold to Buy and raises the price target from $17.5 to $25.

Upgrades

Price Target

Analyst Ratings

TD Cowen Upgrades Invesco to Buy, Raises Price Target to $25

Trading Halt: Halted at 6:20:03 a.m. ET - Trading Halt: Halt News Pending

Earnings

Domino's Pizza Reported 5.6% Global Retail Sales Increase Backed By 148 International And 30 US Store Openings

Domino's Pizza's Same Store Sales Rise 3.4% In US And 2.4% Internationally, Ex-FX

Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Outperform and raises the price target from $69 to $73.

Keefe, Bruyette & Woods Maintains Outperform on Comerica, Raises Price Target to $73

GigaMedia Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIGM#NASDAQ">GIGM</a>) today announced that the Company has entered into and executed an agreement to purchase a US$1,500,000 principal amount of convertible promissory note (the "Note") issued by Aeolus Robotics Corporation ("Aeolus"), a global company primarily engaged in designing, manufacturing, processing and sales of intellectual robotics.
&nbsp;
The Note, bearing interest at a rate of 4.5% per annum, shall be due in 36 months, and all or a portion of the principal amount under the Note may be convertible at GigaMedia's option upon maturity, upon prepayment, or when certain events occur, into ordinary shares of Aeolus at a price of US$0.02 per share.
&nbsp;
The purchase and sale of the Note exhibits GigaMedia and Aeolus's mutual commitment to a longer-term strategic relationship. GigaMedia continually reviews its investment alternatives and may enter into additional transactions of Aeolus's securities in accordance with applicable laws.

GIGM

GigaMedia Invests $1.5M in Aeolus Robotics Via Convertible Note With 4.5% Interest Over 3 Years

Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) reported quarterly earnings of $3.81 per share which missed the analyst consensus estimate of $3.93 by 3.15 percent. This is a 5.46 percent decrease over earnings of $4.03 per share from the same period last year. The company reported quarterly sales of $1.15 billion which beat the analyst consensus estimate of $1.14 billion by 0.13 percent. This is a 4.28 percent increase over sales of $1.10 billion the same period last year.

Earnings Beats

Earnings Misses

Domino's Pizza Q2 EPS $3.81 Misses $3.93 Estimate, Sales $1.15B Beat $1.14B Estimate

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Outperform and raises the price target from $102 to $108.

SCHW

Keefe, Bruyette & Woods Maintains Outperform on Charles Schwab, Raises Price Target to $108

SQNS

Sequans Adds 1,264 Bitcoin For $150M, Boosts Treasury Holdings To 2,317 BTC

Keefe, Bruyette &amp; Woods analyst Chris O'Cull maintains Chemung Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHMG#NASDAQ">CHMG</a>) with a Market Perform and raises the price target from $55 to $59.

CHMG

Keefe, Bruyette & Woods Maintains Market Perform on Chemung Financial, Raises Price Target to $59

GLDG

GoldMining Taps Copper Surge With Over 1.7 Billion Pounds In Resources Across Americas

The Ether Machine, Inc. ("the Company" or "The Ether Machine"), a newly formed entity enabling public market investors to access Ethereum yield, announced its public launch today through a definitive business combination agreement between The Ether Reserve, LLC and Dynamix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNX#NASDAQ">DYNX</a>). Upon the closing of the business combination, the combined entity will trade on NASDAQ under the ticker symbol "ETHM".
The Ether Machine is building the largest public vehicle for institutional-grade exposure to&nbsp;Ethereum, offering secure, transparent, and compliant access to ETH-denominated yield. As a strategic Ether generation company, it aims to deliver long-term, risk-adjusted returns through staking, restaking, and decentralized finance strategies.

IPOs

DYNX

The Ether Machine to Go Public via Merger With Dynamix, Will Trade on NASDAQ as 'ETHM'

Priscilla Chan says advanced GPU clusters aren't just a lure for Silicon Valley, biologists want them, too.
What Happened: Speaking on Ashlee Vance's Core Memory <a href="https://www.youtube.com/watch?v=F1-MFboIASg">podcast</a>, the Chan Zuckerberg Initiative (CZI) co‑founder said the nonprofit now fields roughly 1,000 high‑end graphics chips and is buying more so researchers can do the work they want to do, even if CZI cannot match Big Tech salaries.
Her remarks land as husband Mark Zuckerberg's new Superintelligence Labs woos AI engineers with eight‑figure packages and a pledge to control 1.3 million GPUs by year‑end.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Priscilla Chan&#039;s Multi-Billion Dollar Quest to End Disease" width="500" height="281" src="https://www.youtube.com/embed/F1-MFboIASg?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
"The other thing researchers really care about is access to GPUs," Chan said. "You're not going to make the most of someone if you don't actually have the GPUs for them to work from." CZI's cluster sits at about 1,000 GPUs, with plans to keep growing, she added.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46511927/dave-portnoys-10-million-elon-musk-bet-pays-off-as-tesla-soars-12-in-two-weeks-thats-a-million-bucks">Dave Portnoy&#8217;s $10 Million Elon Musk Bet Pays Off As Tesla Soars 12% In Two Weeks: &#8216;That&#8217;s A Million Bucks&#8217;</a>
Chan tells candidates, "Come work with us because we're going to have the computing power to support the research that you want to do." Pay, she concedes, is "obviously important," yet "we cannot compete with tech companies on this."
The organization has tightened its focus to a "science‑first philanthropy," devoting its biggest bets to biomedical discovery.
Why It Matters: Meta's CEO has a different magnet and that&#8217;s money. Zuckerberg <a href="https://www.threads.com/@theinformation/post/DMGueMrvzTn?xmt=AQF01JbYaFpSpZjtgyA4hVgBJbrdte7zTgFAD6II1raMTQ">told</a> The Information recently that recruits want "the fewest number of people reporting to me and the most GPUs." Meta will spend up to <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43196266/whats-going-on-with-meta-shares-friday-2">$65 billion this year</a> and expects "over 1.3 million graphics processors" online by December.
Meta last week <a href="https://www.benzinga.com/markets/tech/25/07/46434602/mark-zuckerbergs-meta-poaches-top-openai-researchers-jason-wei-and-hyung-won-chung-for-its-superintelligence-lab-report">hired two top researchers</a> from OpenAI for its ambitious new superintelligence lab. This recruitment comes amid a wave of aggressive AI hiring by the company, which has reportedly offered compensation packages of up to $300 million over four years to lure talent from rivals.
That said, analysts warn that Meta's spree will <a href="https://www.benzinga.com/25/01/43214849/mark-zuckerbergs-65-billion-bet-benefits-nvidia-and-other-ai-players-top-analyst-warns-the-run-will-end-in-a-spectacular-bubble-burst">inflate GPU prices</a> and could crowd out nonprofits unless vendors offer discounted cycles.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46513294/nvidia-ceo-jensen-huang-says-hed-ditch-software-for-physical-sciences-if-he-were-20-today">Nvidia CEO Jensen Huang Says He&#8217;d Ditch Software For Physical Sciences If He Were 20 Today</a></li>
</ul>
Image Via Shutterstock

Tech

Mark Zuckerberg's Wife Priscilla Chan Reveals Her Secret Weapon To Lure Top Talent To CZI — And It's Not Eight-Figure Salaries Like Her Husband Offers At Meta

Wag! Initiates Chapter 11 Proceeding In Delaware Court As Part Of Recapitalization With Primary Lender Retriever

U.S. GoldMining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USGO#NASDAQ">USGO</a>) ("U.S. GoldMining" or the "Company") is&nbsp;pleased to provide an update on the Whistler Gold-Copper Project (the "Project") in Alaska, U.S.A. The Company is currently preparing and mobilizing for the 2025 field season which will focus on developing new potential porphyry gold-copper drill targets within the Whistler Orbit and undertaking follow-up mapping and sampling at the Muddy Creek prospect.
2025 Planned Exploration Program Highlights:
<ul>
<li>The 2025 exploration program expands the scope from previous seasons, which focused on delineating and growing the Whistler deposit. As the Company advances its previously announced initial assessment study ("PEA") for the Project (see news release dated June 9, 2025) with the objective of defining a potential economic base-case mining opportunity, the Company's exploration focus now turns to developing a pipeline of exploration targets at the district-scale, which aims to deliver additional future potential mineral resources over the longer term. &nbsp;</li>
<li>The focus of the planned 2025 exploration program (the "Program") is to develop new drill targets for potential gold-copper mineralization within the Whistler – Raintree mineral system, also referred to as the 'Whistler Orbit', which comprises a classic 'porphyry cluster' spread over an area of approximately 5 x 5 km, containing multiple mapped and interpreted porphyry intrusions and including the established Whistler and Raintree West mineral resource deposits. &nbsp;</li>
<li>The Program will also include follow-up mapping and sampling of the&nbsp;Muddy Creek mineral system – a large gold-in-soil geochemical footprint over an area of approximately 6 km x 4 km with an intrusion-related gold geochemical signature.&nbsp;</li>
</ul>

USGO

US GoldMining Expands 2025 Exploration in Alaska to Unlock New Gold-Copper Targets at Whistler Project

Linde Announces New Industrial Gas Investments In Florida And Texas To Support Expanding U.S. Space Sector

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4471431-1&amp;h=1680043096&amp;u=https%3A%2F%2Fwww.westpharma.com%2F&amp;a=West+Pharmaceutical+Services%2C+Inc.">West Pharmaceutical Services, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed&nbsp;Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition. &nbsp;

Management

West Pharmaceutical Names Robert McMahon as New CFO, Succeeding Retiring Finance Chief Bernard Birkett

Shares of Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) rose sharply in pre-market trading ahead of the S&amp;P 500 debut of the Jack Dorsey-founded <a href="https://www.benzinga.com/quote/XYZ">fintech company</a>.
Block will replace Hess Corp. in the S&amp;P 500 effective prior to the opening of trading on Wednesday, July 23.
Block shares jumped 9.6% to $79.81 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>GlucoTrack, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares jumped 82% to $10.61 in pre-market trading.</li>
<li>Dynamix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNX#NASDAQ">DYNX</a>) surged 55.4% to $15.73 in pre-market trading. The Wall Street Journal reported Dynamix plans merger to form The Ether Machine.</li>
<li>TNF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares gained 54% to $0.1347 in pre-market trading after declining around 8% on Friday.</li>
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) rose 42.2% to $0.8674 in pre-market trading after jumping 65% on Friday.</li>
<li>LM Funding America, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) gained 27.8% to $4.13 in pre-market trading after gaining more than 45% on Friday.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) climbed 27.3% to $0.0598 in pre-market trading after gaining 13% on Thursday.</li>
<li>180 Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) rose 18.1% to $2.22 in pre-market trading.</li>
<li>Solid Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) surged 14.1% to $4.30 in pre-market trading after gaining 17% on Friday.</li>
<li>Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) surged 12.3% to $2.53 in pre-market trading after gaining 36% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) dipped 15.2% to $1.34 in pre-market trading after gaining 52% on Friday.</li>
<li>Telomir Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) dipped 13.6% to $1.97 in pre-market trading. Telomir Pharmaceuticals shares jumped 88% on Friday after the company announced data for its gene silencing of STAT1.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) declined 11.3% to $3.78 in pre-market trading after the company updated its revenue guidance for the fiscal year 2025.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares tumbled 10% to $11.77 in pre-market trading after jumping over 58% on Friday.</li>
<li>K-TECH Solutions Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMRK#NASDAQ">KMRK</a>) fell 8.2% to $2.25 in pre-market trading after dipping 45% on Friday.</li>
<li>Majestic Ideal Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MJID#NASDAQ">MJID</a>) declined 7.9% to $3.04 in pre-market trading after dipping 45% on Friday.</li>
<li>Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) fell 7.1% to $0.0798 in pre-market trading after declining around 9% on Friday.</li>
<li>Adicet Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) fell 7.1% to $0.7061 in pre-market trading after falling 4% on Friday.</li>
<li>Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) fell 6.4% to $15.79 in pre-market trading. Webull filed for up to 75.16 million share ordinary stock offering by selling shareholder.</li>
<li>SaverOne 2014 Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) shares fell 4% to $2.86 in pre-market trading after jumping 18% on Friday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Trading Ideas

ACET

ATNF

BULL

CYCC

GCTK

IXHL

KMRK

LMFA

MJID

OPEN

SLDP

SVRE

TELO

TNFA

WLGS

XPON

Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

Outlook
The Company updated previously guided expectations for the full-year 2025, as follows:
<ul>
<li>Capital expenditures of approximately $600 million, from its previous expectation of $625 million</li>
<li>Selling, general and administrative expenses of approximately $575 million, from its previous expectation of approximately $600 million</li>
<li>Steel unit cost reductions maintained at a reduction of approximately $50 per net ton compared to 2024</li>
<li>Depreciation, depletion and amortization of approximately $1.2 billion, from its previous expectation of approximately $1.1 billion, primarily due to accelerated depreciation from idled facilities</li>
<li>Cash Pension and OPEB payments and contributions maintained at approximately $150 million</li>
</ul>

Guidance

Cleveland-Cliffs Cuts 2025 Capex To $600M From $625M, Lowers SG&A To $575M From $600M, Hikes Depreciation To $1.2B From $1.1B

Press Releases

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Legal

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for Information

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd. And Encourages Investors to Contact the Firm

URGN Class Action News: UroGen Pharma Ltd. Investors with Large Losses Should Contact Robbins LLP Before July 28 for Information About Leading the Class Action

UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in UroGen Pharma (URGN) to Inquire About Their Rights in Class Action Lawsuit

Comments

UroGen Pharma

Vendite allo scoperto

UroGen Pharma (NASDAQ:URGN) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO